Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02541903 · ClinicalTrials.gov registry record · Phase 2
Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02541903 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 8 participants.
The verdict
NCT02541903, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Penile squamous cell carcinoma (PSCC) is a highly aggressive and relatively rare disease. Supportive evidence for the value of systemic therapy does not exist for this disease and there are no agents currently approved by regulatory agencies. This study will evaluate the drug Gilotrif in patients with metastatic progressive PSCC following chemotherapy. Gilotrif has shown supportive evidence in non-small cell lung cancer by inhibiting certain proteins that are also found in PSCC. The drug has the potential for some patients to exhibit a response contributing to a greater quality of life.
Interventions
- DRUG Gilotrif
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-10 |
| Est. Completion | 2020-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02541903
The ClinicalTrials.gov registry entry for NCT02541903 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gilotrif is the first listed.
NCT02541903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02541903 about?
NCT02541903 is a clinical study titled "Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma". Penile squamous cell carcinoma (PSCC) is a highly aggressive and relatively rare disease. Supportive evidence for the value of systemic therapy does not exist for this disease and there are no agents currently approved by regulatory agencies. This study will evaluate the drug Gilotrif in patients wi...
What is the current status of trial NCT02541903?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2015-10. Estimated completion is 2020-04.
What interventions are being tested in trial NCT02541903?
The interventions under investigation include: Gilotrif (DRUG).
Who is sponsoring clinical trial NCT02541903?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.